The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer's Disease During the COVID-19 Crisis.
Aged
Aged, 80 and over
Alzheimer Disease
/ epidemiology
Betacoronavirus
COVID-19
Cohort Studies
Coronavirus Infections
/ epidemiology
Female
Humans
Male
Mental Disorders
/ epidemiology
Mental Status and Dementia Tests
Middle Aged
Pandemics
Pneumonia, Viral
/ epidemiology
Quarantine
/ psychology
SARS-CoV-2
Alzheimer’s disease
COVID-19
confinement
neuropsychiatric symptoms
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2020
2020
Historique:
pubmed:
23
6
2020
medline:
16
7
2020
entrez:
23
6
2020
Statut:
ppublish
Résumé
Neuropsychiatric symptoms, such as depression, anxiety, apathy, agitation, and hallucinations, are frequent in Alzheimer's disease (AD) and their prevalence tends to increase with external stressors. We offer the first investigation of the effects of confinement during the COVID-19 crisis on neuropsychiatric symptoms in patients with AD. We contacted caregivers of 38 patients with AD who were confined to their homes for nearly two months and asked them to report whether patients experienced any change in neuropsychiatric symptoms during, compared to before, the confinement and rate its severity and impact on themselves using the Neuropsychiatric Inventory-Questionnaire. Among the 38 patients, only 10 demonstrated neuropsychiatric changes during the confinement. Cognitive function of these 10 patients, assessed with the Mini-Mental State Examination, was worse than that of patients who did not demonstrate neuropsychiatric changes. Interestingly, among the 10 patients with neuropsychiatric changes, the duration of confinement significantly correlated with the severity of symptoms as well as with their caregivers' distress. The confinement seems to impact neuropsychiatric symptomatology in AD patients with low baseline cognitive function.
Sections du résumé
BACKGROUND
Neuropsychiatric symptoms, such as depression, anxiety, apathy, agitation, and hallucinations, are frequent in Alzheimer's disease (AD) and their prevalence tends to increase with external stressors.
OBJECTIVE
We offer the first investigation of the effects of confinement during the COVID-19 crisis on neuropsychiatric symptoms in patients with AD.
METHODS
We contacted caregivers of 38 patients with AD who were confined to their homes for nearly two months and asked them to report whether patients experienced any change in neuropsychiatric symptoms during, compared to before, the confinement and rate its severity and impact on themselves using the Neuropsychiatric Inventory-Questionnaire.
RESULTS
Among the 38 patients, only 10 demonstrated neuropsychiatric changes during the confinement. Cognitive function of these 10 patients, assessed with the Mini-Mental State Examination, was worse than that of patients who did not demonstrate neuropsychiatric changes. Interestingly, among the 10 patients with neuropsychiatric changes, the duration of confinement significantly correlated with the severity of symptoms as well as with their caregivers' distress.
DISCUSSION
The confinement seems to impact neuropsychiatric symptomatology in AD patients with low baseline cognitive function.
Identifiants
pubmed: 32568211
pii: JAD200604
doi: 10.3233/JAD-200604
pmc: PMC9988367
mid: NIHMS1878114
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
41-47Subventions
Organisme : Intramural NIH HHS
ID : Z99 AG999999
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA AG000975
Pays : United States
Références
Am J Geriatr Psychiatry. 2013 Jul;21(7):685-95
pubmed: 23567400
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Br J Psychiatry. 1994 Jul;165(1):53-9
pubmed: 7953058
Dement Geriatr Cogn Dis Extra. 2014 Dec 18;4(3):509-16
pubmed: 25685141
Cogn Neuropsychiatry. 2016;21(1):1-13
pubmed: 26740416
Clin Imaging. 2006 Nov-Dec;30(6):388-93
pubmed: 17101407
Alzheimers Dement (N Y). 2017 Aug 05;3(3):440-449
pubmed: 29067350
Psychol Neuropsychiatr Vieil. 2009 Dec;7 Spec No 1:15-20
pubmed: 20061229
J Affect Disord. 2016 Jan 15;190:264-271
pubmed: 26540080
Am J Geriatr Psychiatry. 2011 Jun;19(6):532-42
pubmed: 21606896
Alzheimers Dement. 2017 Jan;13(1):84-100
pubmed: 27362291
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Science. 2009 Nov 13;326(5955):1005-7
pubmed: 19779148
Alzheimers Dement. 2016 Feb;12(2):195-202
pubmed: 26096665
Neurology. 2015 Feb 10;84(6):617-22
pubmed: 25589671
Int J Geriatr Psychiatry. 1999 Sep;14(9):701-10
pubmed: 10479740
Dialogues Clin Neurosci. 2009;11(2):217-28
pubmed: 19585957
Annu Rev Psychol. 2001;52:59-82
pubmed: 11148299
Am J Geriatr Psychiatry. 2011 Nov;19(11):951-60
pubmed: 21422909
Alzheimers Dement. 2011 Sep;7(5):532-9
pubmed: 21889116
BMJ. 2015 Mar 02;350:h369
pubmed: 25731881
Arch Clin Neuropsychol. 2020 May 22;35(4):377-384
pubmed: 32044967
Mol Aspects Med. 2015 Jun-Oct;43-44:25-37
pubmed: 26049034
Int J Geriatr Psychiatry. 2002 Feb;17(2):184-8
pubmed: 11813283
Cogn Behav Neurol. 2018 Mar;31(1):2-12
pubmed: 29561313
Neurology. 1994 Dec;44(12):2308-14
pubmed: 7991117
Alzheimers Res Ther. 2020 Mar 31;12(1):35
pubmed: 32234066
J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):167-71
pubmed: 10896687
J Alzheimers Dis. 2020;73(3):1143-1156
pubmed: 31884469
Am J Geriatr Psychiatry. 2014 Nov;22(11):1168-79
pubmed: 23890751
Int J Geriatr Psychiatry. 2001 Nov;16(11):1043-53
pubmed: 11746650
Cogn Neuropsychiatry. 2019 Jul;24(4):275-283
pubmed: 31213139
Am J Psychiatry. 2014 May;171(5):572-81
pubmed: 24700290
Conscious Cogn. 2009 Dec;18(4):989-1003
pubmed: 19683461
Ageing Res Rev. 2016 May;27:15-22
pubmed: 26876367
Am J Med Genet B Neuropsychiatr Genet. 2003 May 15;119B(1):40-3
pubmed: 12707936
Am J Geriatr Psychiatry. 2014 Dec;22(12):1642-51
pubmed: 24698445
J Alzheimers Dis. 2019;70(1):25-34
pubmed: 31127783
Am J Psychiatry. 2015 May;172(5):460-5
pubmed: 25585033